

• **Name:**

Ik Jae LEE

• **Current Position:**

Professor, Chief in Department of Radiation Oncology,
Yonsei University Gangnam Severance Hospital, Seoul

• **Country:**

Republic of Korea

• **Educational Background:**

1998-2002 Ph.D. in Radiation Oncology, Yonsei University Medical College Graduate
School, Seoul, Korea

1991-1997 M.D. from Yonsei University College of Medicine, Wonju, Korea

• **Professional Experience:**

2015 -present: Chief in Department of Radiation Oncology,
Yonsei University Gangnam Severance Hospital, Seoul, Korea

2013 -present: Associate professor in Department of Radiation Oncology,
Yonsei University Gangnam Severance Hospital, Seoul, Korea

2009 -2013: Assistant professor in Department of Radiation Oncology,
Yonsei University Gangnam Severance Hospital, Seoul, Korea

2008- 2009: Instructor in Department of Radiation Oncology,
Yonsei University Gangnam Severance Hospital, Seoul, Korea

2007- 2008: Instructor in Department of Radiation Oncology,
Yonsei University, Yonsei Cancer Center, Seoul, Korea

• **Professional Organizations:**

Korean Society for Radiation Oncology

Korean Cancer Association

Korean Society of Medical Oncology

The Korean Liver Cancer Association

American Society for Radiation Oncology

European Society for Radiation Oncology

American Association for Cancer Research

• **Main Scientific Publications:**

1. Ma DW, Cho Y, Jeon MJ et al. Relationship Between Sarcopenia and Prognosis in Patient With Concurrent Chemo-Radiation Therapy for Esophageal Cancer. *Front Oncol.* 2019;8;9:366.
2. Park S, Cha YJ, Suh SH et al. Risk group-adapted adjuvant radiotherapy for WHO grade I and II skull base meningioma. *J Cancer Res Clin Oncol.* 2019;145(5):1351-1360.
3. Cho Y, Cho YJ, Chang WS et al. Evaluation of optimal treatment planning for radiotherapy of synchronous bilateral breast cancer including regional lymph node irradiation. *Radiat Oncol.* 2019;14(1):56.
4. Kim JW, Cho Y, Kim HS et al. A phase II study of intraoperative radiotherapy using a low-energy x-ray source for resectable pancreatic cancer: A study protocol. *BMC Surg.* 2019;19(1):31.
5. Kim TH, Lee IJ, Kim JH et al. High-dose versus standard-dose radiation therapy for cervical esophageal cancer: Retrospective single-institution study. *Head Neck.* 2019;41(1):146-153.
6. Koo T, Lim DH, Seol HJ et al. Impact of adjuvant treatments on survival in Korean patients with WHO grade II gliomas: KNOG 15-02 and KROG 16-04 intergroup study. *J Neurooncol.* 2018;140(2):445-455.
7. Cho Y, Kim JW, Yoon HI et al. The Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Head and Neck Cancer Patients Treated with Radiotherapy. *J Clin Med.* 2018;7:512-524.
8. Koo T, Lim DH, Seol HJ et al. Multi-institutional study of treatment patterns in Korean patients with WHO grade II gliomas: KNOG 15-02 and KROG 16-04 intergroup study. *J Neurooncol.* 2018;138(3):667-677.
9. Cho Y, Kim JW, Keum KC et al. Prognostic Significance of Sarcopenia With Inflammation in Patients With Head and Neck Cancer Who Underwent Definitive Chemoradiotherapy. *Front Oncol.* 2018;8:457-466.
10. Choi J, Kim JW, Jeon TJ et al. The 18F-FDG PET/CT response to radiotherapy for patients with spinal metastasis correlated with the clinical outcomes. *PLoS One.* 2018;13(9):e0204918.
11. Jang JY, Han Y, Lee H et al. Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial. *Ann Surg.* 2018;268(2):215-222.
12. Park JW, Choi SH, Yoon HI et al. Treatment outcomes of radiotherapy for anaplastic thyroid cancer. *Radiat Oncol J.* 2018;36(2):103-113.
13. Choi SH, Kim JW, Choi J et al. Locoregional Treatment of the Primary Tumor in Patients with De Novo Stage IV Breast Cancer: A Radiation Oncologist's Perspective. *Clin Breast Cancer.* 2018;18(2):e167-e178.
14. Chang JS, Lee J, Chun M et al. Mapping patterns of locoregional recurrence following contemporary treatment with radiation therapy for breast cancer: A multi-institutional validation study of the ESTRO consensus guideline on clinical target volume. *Radiation Oncol.* 2018;126(1):139-147.
15. Kim JW, Kim TH, Kim JH et al. Predictors of post-treatment stenosis in cervical esophageal cancer undergoing high-dose radiotherapy. *World J Gastroenterol.* 2018;24(7):862-869.
16. Yeo CD, Lee MK, Lee SH et al. Indicators and Qualitative Assessment of Lung Cancer Management by Health Insurance Review and Assessment Service (HIRA) of Korea in 2015. *Tuberc Respir Dis (Seoul).* 2018;81(1):19-28.
17. Kim JW, Byeon HK, Choi HS et al. Dose de-escalation to the normal larynx using conformal radiotherapy reduces toxicity while maintaining oncologic outcome for T1/T2 glottic cancer. *Sci Rep.* 2017;7(1):15732.
18. Kim JW, Suh CO, Hong CK et al. Maximum surgical resection and adjuvant intensity-modulated radiotherapy with simultaneous integrated boost for skull base chordoma. *Acta Neurochir (Wien).* 2017;159(10):1825-1834.
19. Kim JK, Kim JW, Lee IJ et al. Factors affecting survival after concurrent chemoradiation therapy for advanced hepatocellular carcinoma: a retrospective study. *Radiat Oncol.* 2017;12(1):133.
20. Lee JJB, Choi J, Ahn SG et al. In vivo dosimetry and acute toxicity in breast cancer patients undergoing intraoperative radiotherapy as boost. *Radiat Oncol J.* 2017;35(2):121-128.
21. Kim KH, Chang JS, Cha JH et al. Optimal Adjuvant Treatment for Curatively Resected Thoracic Esophageal Squamous Cell Carcinoma: A Radiotherapy Perspective. *Cancer Res Treat.* 2017;49(1):168-177.
22. Chang JS, Byun HK, Kim JW et al. Three-dimensional analysis of patterns of locoregional recurrence after treatment in breast cancer patients: Validation of the ESTRO consensus guideline on target volume. *Radiation Oncol.* 2017;122(1):24-29.